Trial reportBMC neurology2009
Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study.
Trial report in BMC neurology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 79 citations in OpenAlex.
- Gray Matter Volume Loss in Parkinson's Disease Psychosis and Cannabinoid Receptor Gene Expression in the Brain.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Antipsychotic Medications in Parkinson's Disease Psychosis; A Systematic Review of Double-Blind, Randomised, Placebo-Controlled Trials.Healthcare (Basel, Switzerland) · 2026Review
- Article
- On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson's Disease Psychosis.CNS drugs · 2024Article
- Case Files of the Emory University Medical Toxicology Fellowship: A Patient Presents to the Outpatient Toxicology Clinic with Delusions of Being Poisoned.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2024Article
- Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.Neurology and therapy · 2023Article
- Pimavanserin: A Truly Effective Treatment for Parkinson's Disease Psychosis? A Review of Interventions.Neuropsychiatric disease and treatment · 2023Review
- Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis.International journal of molecular sciences · 2021Review
- Overlapping Genetic Architecture Between Schizophrenia and Neurodegenerative Disorders.Frontiers in cell and developmental biology · 2021Article
- New evidence on the management of Lewy body dementia.The Lancet. Neurology · 2020Review
- Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist.Endocrine connections · 2018Review
- Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy.Journal of neural transmission (Vienna, Austria : 1996) · 2017Article
- Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management.Drugs & aging · 2016Review
- Review
- The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's Disease.Behavioural neurology · 2016Review
- Modeling nigrostriatal degeneration in organotypic cultures, a new ex vivo model of Parkinson's disease.Neuroscience · 2014Article
- Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson's disease.Frontiers in aging neuroscience · 2014Article
- Synaptic plasticity, neural circuits, and the emerging role of altered short-term information processing in schizophrenia.Frontiers in synaptic neuroscience · 2014Review
- Pramipexole induced psychosis in a patient with restless legs syndrome.BMJ case reports · 2013Article
- The effect of dopamine agonists on adaptive and aberrant salience in Parkinson's disease.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPsychosis is rare in untreated patients with Parkinson's disease (PD) but the prevalence rises to 40% during dopaminergic treatment. So far, no systematic comparison of the psychogenic potential of different dopaminergic drugs had been performed.
methodsEighty PD patients with psychotic episodes were compared to an age-matched control group of PD patients without psychotic episodes (n = 120) in a cross-sectional retrospective study.
resultsWe found a positive correlation between psychotic episodes and dementia, number of concomitant medication, and pergolide intake. Odds ratio calculation confirmed the association with dementia. With respect to dopaminergic treatment, pergolide showed the highest odds ratio, levodopa the lowest. An adjusted logistic regression model confirmed the strong association with psychotic episodes and pergolide and no association with levodopa (adjusted odds ratio 2.01 and 0.11, respectively).
conclusionThe analysis indicates that dementia and concomitant medication are factors in PD associated with psychotic symptoms. Furthermore, different dopaminergic drugs showed markedly different associations with psychotic symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.